Coronary Artery DiseasePOSTERNCT03520140
Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease
An observational study of Coronary Artery Disease, run by Heart Care Foundation at 81 sites in Italy.
Trial summary
Evaluate the prevalence of familial hypercholesterolemia (FH) in patients with documented coronary artery disease (CAD) event [acute myocardial infarction (AMI), acute coronary syndrome (ACS), coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)] followed by 100 cardiological centers… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 5,415 participants
- Where
- 81 sitesItaly
- Study dates
- 15 Jun 2016to 30 May 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients must have a documented coronary artery disease, more precisely: ACS PCI CABG The index event must be occurred between 15 days and 8 weeks preceding the enrollment
Who may be able to join
- Patients must have a documented coronary artery disease, more precisely:
- ACS PCI CABG The index event must be occurred between 15 days and 8 weeks preceding the enrollment.
- Written informed consent to participate to the study
Who cannot join
- Patients unwilling to give their written informed consent.
Trial locations and contacts
81 sites in 1 country.
81 sites in 1 country
Italy81 sites
Istituto Scientifico Inrca - Uo Cardiologia/Utic/Telecardiologia
Ancona
Ospedali Riuniti - Sod Cardiologia Ospedaliera Emod. E Utic
Ancona
Osp. Andria Canosa - Po Andria - Cardiologia - Utic
Andria
Ospedale Generale Regionale-Po U. Parini - U.O. Cardiologia E Cure Intensive Card.
Aosta
Ospedale Civile - U.O.C. Cardiologia
Arzignano
Ospedale Gen.Le Prov.Le C.G. Mazzoni - Sc Cardiologia
Ascoli Piceno
Ospedale E. Muscatello - U.O. Di Cardiologia - Utic
Augusta
Presidio Ospedaliero Moscati - U.O.C. Cardiologia
Aversa
Ospedale Policlinico - U.O. Cardiologia Universitaria
Bari
Ospedale San Paolo - Cardiologia-Utic
Bari
Azienda Ospedaliera G. Rummo - Cardiologia Interventistica E Utic
Benevento
Ospedale Maggiore - U.O. Di Cardiologia
Bologna
Ospedale Generale Regionale - Ospedale Generale Regionale Divisione Di Cardiologia
Bolzano
Ospedale Ss. Trinita' - S.C. Di Cardiologia
Borgomanero
Azienda Ospedaliera G. Brotzu - Struttura Complessa Di Cardiologia
Cagliari
Ospedale San Giovanni Di Dio - Clinica Cardiologica
Cagliari
Ospedale A. Cardarelli - U.O. Cardiologia E Utic
Campobasso
Presidio Ospedaliero F. Ferrari - Cardiologia - Utic
Casarano
Az. Ospedaliera S. Anna E S. Sebastiano - U.O. Cardiologia-Utic
Caserta
P.O. Garibaldi-Nesima - U.O.C. Di Cardiologia
Catania
Fondazione G. Giglio - U.O. Cardiologia E Utic
Cefalù
Ospedale Bassini - U.O. Cardiologia E Utic
Cinisello Balsamo
Ospedale Di Cittadella - U.O. Cardiologia
Cittadella
Ospedale San Giuseppe Da Copertino - U.O. Di Cardiologia-Utic
Copertino
Ospedale Valdichiana Santa Margherita - Uos Cardiologia E Hdu
Cortona
Maria Cecilia Hospital - U.O. Di Cardiologia
Cotignola
Ospedale Di Cremona - Uo Di Cardiologia
Cremona
Ospedale Civile Sant'Antonio Abate - U.O.C. Di Cardiologia E Utic
Erice
Ospedale Civile - U.O.C. Cardiologia - Utic
Fidenza
Aou Careggi - Interventistica Cardiologica Strutturale
Florence
Aou Careggi - Riabilitazione Cardiologica
Florence
Ospedale Santa Maria Nuova - Hdu Cardiologica/Utic
Florence
Ospedali Riuniti - S.C. Di Cardiologia Univ.-Utic
Foggia
Ospedale G.B. Morgagni - L. Pierantoni - U.O. Cardiologia
Forlì
E.O. Ospedali Galliera - S. C. Cardiologia
Genova
Ospedale Civile - Sc Cardiologia Area Nord
Guastalla
Citta' Di Lecce Hospital - U.O. Di Cardiologia
Lecce
Nuovo Ospedale Versilia - Sc Cardiologia
Lido di Camaiore
Ospedale Civile M. Giannuzzi - Cardiologia E Utic
Manduria
Presidio Ospedaliero Paolo Borsellino - U.O.C Cardiologia- Utic
Marsala
Ospedale G. Fucito - U.O. Di Cardiologia E Utic
Mercato San Severino
Policlinico Di Monza - Uo Cardiol. Clinica E Scompenso Cardiaco
Monza
Aorn Cardarelli - U.O. Cardiologia Con Utic
Naples
Aorn Osp. Dei Colli- Po Vincenzo Monaldi - U.O.C. Cardiologia - S.U.N.
Naples
Aou Maggiore Della Carita' - Cardiologia Ii
Novara
Ospedale San Francesco - Cardiologia - Utic
Nuoro
Ospedale San Luigi Gonzaga - S.C.D.O. Cardiologia
Orbassano
Maria Eleonora Hospital - Cardiologia
Palermo
Ospedale Civico - U.O. Cardiologia
Partinico
Centro Cuore Morgagni - U.F. Utic Ed Emodinamica
Pedara
Ospedale Civile Ave Gratia Plena - U.O. Di Cardiologia E Utic
Piedimonte Matese
Ospedale San Jacopo - U.O. Cardiologia
Pistoia
Policlinico Citta' Di Pomezia S. Anna - U.O. Cardiologia-Utic
Pomezia
Ospedale Santa Maria Delle Grazie - U.O. Cardiologia - Utic
Pozzuoli
Arcispedale Santa Maria Nuova - S.C. Cardiologia
Reggio Emilia
Ospedale Infermi - U.O. Cardiologia
Rimini
Campus Biomedico - Cardiologia
Roma
Ospedale Madre Giuseppina Vannini - U.O.C. Cardiologia
Roma
P.O. San Filippo Neri - Asl Roma 1 - Uoc Cardiologia E Utic
Roma
Policlinico Casilino - U.O. Cardiologia
Roma
Policlinico Umberto Primo - Cardiologia B - Cardiologia E Angiologia
Roma
A.O.U.S. Giovanni Di Dio-Ruggi D'Aragona - Sc Di Cardiologia
Salerno
Ospedale G. Fracastoro - U.O.C. Di Cardiologia
San Bonifacio
Ospedale Casa Sollievo Della Sofferenza - Cardiologia - Utic - Riabil Cardiologica
San Giovanni Rotondo
Presidio Ospedaliero - U.O. Cardiologia
Sanremo
Ospedale San Giuseppe E Melorio - U.O.C. Cardiologia Utic
Santa Maria Capua Vetere
Presidio Ospedaliero Di Saronno - U.O.C. Di Cardiologia
Saronno
Ospedale Ignazio Veris Delli Ponti - Uoc Cardiologia-Utic
Scorrano
IRCCS Policlinico Multimedica - UO Cardiologia
Sesto San Giovanni
Ospedale San Matteo Degli Infermi - Servizio Di Cardiologia Con Utic
Spoleto
Ospedale Umberto I - Uoc Cardiologia E Utic
Syracuse
Casa Di Cura Villa Verde - Cardiologia
Taranto
Ospedale San Timoteo - Ssd Cardiologia Emodinamica
Termoli
Centro Polifunzionale Boldrini - Cardiologia Riabilitativa-Cardioaction
Thiene
Aou Citta' Della Salute E Della Scienza-Scdu Cardiologia
Torino
Ospedali Treviglio-Caravaggio - Cardiologia
Treviglio
Ospedali Riuniti - Osp. Maggiore - A.F. Cardiologia E Riabilitazione Cardio
Trieste
Pou Santa Maria Della Misericordia - S.O.C. Cardiologia
Udine
Ospedale Di Circolo E Fondazione Macchi - Ssd Unita' Di Cure Intensive Coronariche
Varese
Ospedale San Pio Da Pietrelcina - Cardiologia
Vasto
Ics Maugeri Spa Societa' Benefit - Uo Cardiologia Riabilitativa
Veruno
About this study
Evaluate the prevalence of familial hypercholesterolemia (FH) in patients with documented coronary artery disease (CAD) event [acute myocardial infarction (AMI), acute coronary syndrome (ACS), coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)] followed by 100 cardiological centers representative of the whole Italian territory
Read the detailed description
Familial hypercholesterolemia (FH) is a disease that causes exposure to elevated plasma levels of LDL cholesterol (LDL-C, low-density lipoprotein) and increasing the risk of premature coronary heart disease (coronary artery disease, CAD). The FH is a co-dominant genetic disease and can occur in heterozygous and homozygous form, with different severity. The prevalence in whites is estimated to be 1.500 for heterozygous familial hypercholesterolemia (HeFH) and 1.1000000 for homozygous familial hypercholesterolemia (HoFH). This prevalence is probably an underestimate, as it is based on prevalence rates in in-patient and disease registries, and is influenced by the early mortality of patients with FH. The situation does not improve if we consider patients admitted for acute coronary event (myocardial infarction - AMI and / or unstable angina, - ACS). If we consider LDL cholesterol cumulative load in a person affected by FH, the best approach intervention to reduce cardiovascular mortality is an early diagnosis and treatment.
The primary aim of the study is to evaluate the prevalence of FH in patients with documented CAD event (AMI, ACS, CABG or PCI) followed by 100 cardiologic centers representative of the whole Italian territory. The results will also permit to increase the cardiologists awareness of FH. Secondary objective will be the validation of Dutch Lipid Clinic Network (DLCN) criteria (annex 1), in the Italian CAD population (12). The characterization of the patients, carried out during the study, will allow to identify the priorities for health inteventions aimed at improving the FH diagnosis in the general population through the a cascade screening in the relatives of the genetically characterized subjects.
- Conditions
- Coronary Artery Disease
- Keywords
- Familial hypercholesterolemia, Coronary artery disease
- Medical subject headings
- Coronary Artery Disease, Hyperlipoproteinemia Type II
What is being measured
The primary outcome is the main question the study is designed to answer.
Familial hypercholesterolemia diagnosis
Dutch Lipid Clinic Network Score (DLCNS) for FH The DLCNS is a validated set of criteria based on the patients family history of premature cardiovascular disease (CVD) in their first degree relatives, their own CVD history, their untreated lipid levels and physical signs such as the presence of tendon xanthomata or arcus cornealis prior to the age of 45. The subsequent score categorizes patients by the likelihood of Familial Hypercholesterolaemia (FH) diagnosis.
Definite FH if score >8 Probable FH if score 6-8 Possible FH if score 3-5 Unlikely FH if score <3
Measured: Inclusion
Genetic examination
Sequencing of (LDLR, APOB, PVSK9 and LDLRAP1)
Measured: Inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2018
- Study start15 Jun 2016
- Primary completion30 May 2018
- Study completion30 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,415 participants (actual)
Sponsor and investigators
- Lead sponsor
- Heart Care Foundation
- Sponsor type
- University, hospital or other
- Collaborators
- Fondazione SISA
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03520140
- Sponsor's protocol ID
- K18
- Acronym
- POSTER
- Status last verified
- Apr 2018
- First submitted
- 13 Apr 2018
- Last updated
- 9 Oct 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gulizia MM, Maggioni AP, Abrignani MG, Bilato C, Mangiacapra F, Sanchez FA, Piovaccari G, Montagna L, Marini M, De Biasio M, Averna M, Casula M, Colivicchi F, Fabbri G, Lucci D, Zampoleri V, Catapano AL; POSTER Investigators. Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis. 2020 Sep;308:32-38. doi: 10.1016/j.atherosclerosis.2020.07.007. Epub 2020 Jul 29.
PubMed 32823190Qureshi N, Da Silva MLR, Abdul-Hamid H, Weng SF, Kai J, Leonardi-Bee J. Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. Cochrane Database Syst Rev. 2021 Oct 7;10(10):CD012985. doi: 10.1002/14651858.CD012985.pub2.
PubMed 34617591
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT03520140
- Acronym / sponsor ID
- POSTER / K18
- Conditions
- Coronary Artery Disease
- Keywords
- Familial hypercholesterolemia, Coronary artery disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,415 participants (actual)
- Lead sponsor
- Heart Care FoundationUniversity, hospital or other
- Collaborators
- Fondazione SISA
- Study start
- 15 Jun 2016 (actual)
- Primary completion
- 30 May 2018 (actual)
- Study completion
- 30 May 2018 (actual)
- First posted
- 9 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluate the prevalence of familial hypercholesterolemia (FH) in patients with documented coronary artery disease (CAD) event [acute myocardial infarction (AMI), acute coronary syndrome (ACS), coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)] followed by 100 cardiological centers representative of the whole Italian territory
Detailed description
Familial hypercholesterolemia (FH) is a disease that causes exposure to elevated plasma levels of LDL cholesterol (LDL-C, low-density lipoprotein) and increasing the risk of premature coronary heart disease (coronary artery disease, CAD). The FH is a co-dominant genetic disease and can occur in heterozygous and homozygous form, with different severity. The prevalence in whites is estimated to be 1.500 for heterozygous familial hypercholesterolemia (HeFH) and 1.1000000 for homozygous familial hypercholesterolemia (HoFH). This prevalence is probably an underestimate, as it is based on prevalence rates in in-patient and disease registries, and is influenced by the early mortality of patients with FH. The situation does not improve if we consider patients admitted for acute coronary event (myocardial infarction - AMI and / or unstable angina, - ACS). If we consider LDL cholesterol cumulative load in a person affected by FH, the best approach intervention to reduce cardiovascular mortality is an early diagnosis and treatment.
The primary aim of the study is to evaluate the prevalence of FH in patients with documented CAD event (AMI, ACS, CABG or PCI) followed by 100 cardiologic centers representative of the whole Italian territory. The results will also permit to increase the cardiologists awareness of FH. Secondary objective will be the validation of Dutch Lipid Clinic Network (DLCN) criteria (annex 1), in the Italian CAD population (12). The characterization of the patients, carried out during the study, will allow to identify the priorities for health inteventions aimed at improving the FH diagnosis in the general population through the a cascade screening in the relatives of the genetically characterized subjects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients must have a documented coronary artery disease, more precisely: ACS PCI CABG The index event must be occurred between 15 days and 8 weeks preceding the enrollment
Key inclusion criteria (3 listed)
- Patients must have a documented coronary artery disease, more precisely:
- ACS PCI CABG The index event must be occurred between 15 days and 8 weeks preceding the enrollment.
- Written informed consent to participate to the study
Key exclusion criteria (1 listed)
- Patients unwilling to give their written informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Familial hypercholesterolemia diagnosis
Time frame: Inclusion
Dutch Lipid Clinic Network Score (DLCNS) for FH The DLCNS is a validated set of criteria based on the patients family history of premature cardiovascular disease (CVD) in their first degree relatives, their own CVD history, their untreated lipid levels and physical signs such as the presence of tendon xanthomata or arcus cornealis prior to the age of 45. The subsequent score categorizes patients by the likelihood of Familial Hypercholesterolaemia (FH) diagnosis. Definite FH if score >8 Probable FH if score 6-8 Possible FH if score 3-5 Unlikely FH if score <3
Genetic examination
Time frame: Inclusion
Sequencing of (LDLR, APOB, PVSK9 and LDLRAP1)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2020.
- Results publication: PubMed 32823190Gulizia MM, Maggioni AP, Abrignani MG, Bilato C, Mangiacapra F, Sanchez FA, Piovaccari G, Montagna L, Marini M, De Biasio M, Averna M, Casula M, Colivicchi F, Fabbri G, Lucci D, Zampoleri V, Catapano AL; POSTER Investigators. Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis. 2020 Sep;308:32-38. doi: 10.1016/j.atherosclerosis.2020.07.007. Epub 2020 Jul 29.
- Derived from this study: PubMed 34617591Qureshi N, Da Silva MLR, Abdul-Hamid H, Weng SF, Kai J, Leonardi-Bee J. Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. Cochrane Database Syst Rev. 2021 Oct 7;10(10):CD012985. doi: 10.1002/14651858.CD012985.pub2.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
81 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Heart Care Foundation at 81 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 81 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Familial hypercholesterolemia diagnosis (time frame: Inclusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03520140, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2020.